ARLINGTON, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that its network of affiliated medical groups, collectively Privia Medical Group, has been named a recipient of the 2026 MAP (Measure, Apply, Perform) Award for High Performance in Revenue Cycle, sponsored by the Healthcare Financial Management Association (HFMA). Privia Health has been recognized by HFMA for its revenue cycle capabilities and performance in nine of the last ten years. The MAP Award is one ...

Core Insights - David Mountcastle, EVP & CFO of Privia Health Group, sold 13,018 shares for approximately $283,000, primarily to cover tax obligations related to the vesting of performance stock units [1][7]. Transaction Summary - The direct sale involved 13,018 shares with a total transaction value of $283,000 [2]. - Post-transaction, Mountcastle holds 226,804 direct shares and 8,695 indirect shares, with a direct ownership stake of 0.18% of the company's outstanding shares [5][2]. Company Overview - Privia Health Group has a market capitalization of $2.61 billion and reported a revenue of $2.12 billion with a net income of $22.92 million for the trailing twelve months [4]. - The company's stock price has decreased by 10.15% over the past year as of March 21, 2026 [4]. Financial Performance - In Q4 FY 2025, Privia exceeded earnings expectations, reporting earnings of 7 cents per share, surpassing the 4-cent estimate and marking the highest year-over-year growth since Q3 2023 [8]. Growth Strategy - Privia is optimistic about its growth in value-based operations following the acquisition of an Accountable Care Organization (ACO) in late September 2025, which added approximately 1.5 million customers with various medical plans [9].

Privia Health (PRVA) closed the last trading session at $22.1, gaining 0.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.7 indicates a 43.4% upside potential.The average comprises 20 short-term price targets ranging from a low of $23.00 to a high of $40.00, with a standard deviation of $3.48. While the lowest estimate indicates an increase of 4.1% from the current price leve ...

Core Insights - Amalgam Rx, Inc. announced results from a colorectal cancer screening program led by Privia Health, showcasing the effectiveness of EHR-integrated workflows and proactive patient outreach in increasing screening rates [1] Group 1: Company Overview - Amalgam Rx, Inc. is recognized as a leader in data-driven, AI-powered healthcare engagement and clinical decision support [1] - The company collaborated with Privia Health and Exact Sciences Corp. to support the colorectal cancer screening initiative [1] Group 2: Program Results - The colorectal cancer screening program demonstrated a significant increase in screening rates, as documented in a published case study by Privia Health [1] - The integration of electronic health records (EHR) and proactive outreach strategies were key components in enhancing patient engagement and screening participation [1]

Group 1 - Shares of Privia Health (PRVA) have increased by 8.9% over the past four weeks, closing at $24.91, with a mean price target of $31.25 indicating a potential upside of 25.5% [1] - The mean estimate consists of 20 short-term price targets with a standard deviation of $2.99, where the lowest estimate is $23.00 (7.7% decline) and the highest is $37.00 (48.5% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as indicated by a 1.7% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - PRVA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While price targets are often viewed as misleading, the direction indicated by the consensus price target may serve as a useful guide for investors [10][14] - Analysts' price targets can be influenced by business relationships, leading to potentially inflated estimates, but a low standard deviation among targets suggests a consensus on price movement direction [8][9]

Financial Obligations and Risks - The company is required to maintain certain financial condition tests under the Revolving Credit Agreement, which can be affected by uncontrollable events [219]. - A breach of covenants in the Revolving Credit Agreement could lead to an event of default, allowing creditors to accelerate debt payments [220]. - The company may need to raise additional capital to expand operations and invest in new technologies, which could limit operational flexibility [222]. - The company is obligated to maintain effective internal control over financial reporting to comply with the Sarbanes-Oxley Act, incurring substantial expenses [223]. Market and Operational Challenges - A deterioration in public health conditions, such as a pandemic, could adversely impact the company's business and operations [225]. - Increased scrutiny on environmental, social, and governance (ESG) initiatives may lead to higher costs and affect the company's reputation [226]. - Market conditions, including fluctuations in quarterly financial results and regulatory developments, could lead to volatility in the company's stock price [239]. - The company's primary market risk exposure is rising interest rates, with interest rates on its Credit Agreement ranging from 0.25% to 0.75% [364]. - Inflation has not materially affected the company's operating results, but future inflation could have adverse impacts [365]. Dividend and Investment Returns - The company has no current plans to pay regular cash dividends, meaning returns on investment depend solely on stock price appreciation [238].

Financial Performance - For the quarter ended December 2025, Privia Health reported revenue of $541.17 million, reflecting a year-over-year increase of 17.4% [1] - The earnings per share (EPS) for the quarter was $0.07, compared to $0.03 in the same quarter last year, indicating significant growth [1] - The reported revenue exceeded the Zacks Consensus Estimate of $520.06 million by 4.06%, while the EPS surpassed the consensus estimate of $0.04 by 67.87% [1] Key Metrics - Practice Collections amounted to $868.6 million, which was below the average estimate of $889.58 million from five analysts [4] - Care Margin was reported at $116.5 million, slightly above the estimated $112.77 million by five analysts [4] - Platform Contribution reached $55.1 million, exceeding the average estimate of $54.7 million from five analysts [4] - The number of Implemented Providers at the end of the period was 5,380, surpassing the average estimate of 5,324 from three analysts [4] - Value-Based Care Attributed Lives stood at 1.54 million, exceeding the estimated 1.42 million from three analysts [4] Stock Performance - Shares of Privia Health have returned -0.5% over the past month, while the Zacks S&P 500 composite increased by 0.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Privia Health (PRVA) reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, and showing an increase from $0.03 per share a year ago, resulting in an earnings surprise of +67.87% [1] - The company achieved revenues of $541.17 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.06% and increasing from $460.9 million year-over-year [2] - Privia Health has outperformed consensus revenue estimates four times over the last four quarters, although it has only surpassed consensus EPS estimates once during the same period [2] Earnings Outlook - The future performance of Privia Health's stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $548.11 million, and for the current fiscal year, it is $0.34 on revenues of $2.31 billion [7] Industry Context - The Medical Info Systems industry, to which Privia Health belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Privia Health's stock performance [5]

Financial Data and Key Metrics Changes - Privia Health reported a strong operational performance in 2025, with adjusted EBITDA increasing by 38.8% to $125.5 million, and EBITDA margin expanding by 480 basis points to 27.2% [6][11] - Practice collections for the year increased by 16.9% to reach $3.47 billion, with care margin up 14.4% [12][13] - The company ended 2025 with a cash balance of $479.7 million and no debt, projecting to end 2026 with approximately $600 million in cash [7][14] Business Line Data and Key Metrics Changes - The company added 591 providers, a 12.3% increase year-over-year, ending the year with 5,380 implemented providers [6][11] - Value-based attributed lives increased by 22.7% to 1.54 million, with commercial attributed lives up 16% to 910,000 [6][9] - The acquisition of Evolent Health's ACO business added over 120,000 value-based attributed lives [6][8] Market Data and Key Metrics Changes - Privia Health's national footprint now includes a presence in 24 states and the District of Columbia, with a patient NPS of 87 across its footprint [8][9] - The company reported a 52% increase in lives attributed to CMS Medicaid programs, with Medicare Advantage and Medicaid attribution increasing by 15% and 23%, respectively [9] Company Strategy and Development Direction - The company aims to achieve the Quadruple Aim: better outcomes, lower costs, improved patient experience, and happier providers [5] - Privia Health plans to continue its disciplined and strategic capital deployment while actively seeking business development deals to compound EBITDA and free cash flow [15][42] - The company is focused on enhancing its technology investments, particularly in AI, to improve operational efficiency and margins [18][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a challenging healthcare services environment, expecting EBITDA growth of approximately 20% in 2026 [7][14] - The management highlighted the importance of maintaining a diversified model across various payer types to mitigate risks associated with changes in the healthcare landscape [31][70] - The company anticipates continued strong utilization trends in ambulatory care settings, despite potential churn in Medicaid enrollment [31][32] Other Important Information - The company converted 130% of EBITDA to free cash flow in 2025, with expectations to convert 80% in 2026 as it becomes a full cash taxpayer [7][15] - Management emphasized the importance of maintaining a sufficient cash balance for operational flexibility and potential capital returns [43] Q&A Session Summary Question: Can you speak to tech investments, including AI and advancements for physicians? - Management discussed three components of AI-related investments, focusing on enhancing margins and shareholder returns through data-rich environments and existing technology partnerships [18][19] Question: Can you provide color on Practice Collection trends for Q4 and 2026 guidance? - Management noted that Q4 collections were impacted by prior period adjustments and emphasized focusing on Care Margin growth rather than just Practice Collections [25][28] Question: What are your thoughts on utilization trends with changes around ACA and Medicaid enrollment? - Management indicated that ambulatory utilization remains elevated post-COVID, and the diversified model positions the company well amidst changes in Medicaid [31][32] Question: Can you help bridge historical expectations for EBITDA to free cash flow conversion? - Management highlighted a strong historical average of over 100% conversion and noted that 2026 guidance reflects a more normalized expectation due to cash tax payments [35][36] Question: Any updated thoughts around capital deployment priorities? - Management reiterated the priority of deploying capital to compound the business while maintaining a cash reserve for operational flexibility [41][43] Question: Can you provide an update on the Evolent acquisition and its synergies? - Management expressed excitement about the Evolent acquisition, highlighting opportunities for cross-selling and improving savings rates over time [48][49] Question: Can you confirm the Evolent Care Partners EBITDA and revenue? - Management did not disclose specific numbers but confirmed that the acquisition is contributing meaningfully to overall EBITDA growth [75][77] Question: What have you embedded in your guidance regarding shared savings? - Management stated that guidance is based on prudent accruals and emphasized a diversified book to navigate various risk pools [79][82]

Financial Data and Key Metrics Changes - Privia Health reported a 16.9% increase in practice collections for 2025, reaching $3.47 billion, with adjusted EBITDA growing 38.8% to $125.5 million [6][12][13] - The adjusted EBITDA margin as a percentage of Care Margin expanded by 480 basis points to 27.2% [6][11] - The company ended 2025 with a cash balance of $479.7 million, with a conversion of 130% of EBITDA to free cash flow [7][13] Business Line Data and Key Metrics Changes - The number of implemented providers increased by 12.3% year-over-year to 5,380, with a total of 1.54 million value-based attributed lives, up 22.7% [6][8] - Practice collections in Q4 increased by 9.6% year-over-year, reaching $868.7 million [11] - The company added over 120,000 value-based attributed lives through the acquisition of Evolent Health's ACO business [6][8] Market Data and Key Metrics Changes - Commercial attributed lives increased by more than 16% to 910,000, while lives attributed to CMS Medicaid programs rose by 52% [9] - Medicare Advantage and Medicaid attribution increased by 15% and 23%, respectively, from the previous year [9] Company Strategy and Development Direction - Privia Health aims to achieve the Quadruple Aim: better outcomes, lower costs, improved patient experience, and happier providers [5] - The company plans to continue its growth strategy by actively seeking business development deals in both new and existing markets [15] - The national footprint now includes a presence in 24 states and the District of Columbia, with a focus on maintaining high gross provider retention of 98% [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive EBITDA growth of approximately 20% in 2026, with expectations to convert 80% of EBITDA to free cash flow [7][15] - The management highlighted the importance of navigating the changing healthcare regulatory environment and maintaining a diversified business model [16] - There is an expectation of continued elevated ambulatory utilization, which is seen as beneficial for the business [32] Other Important Information - The company completed the acquisition of Evolent Health's ACO business on December 5, which is expected to enhance its value-based care offerings [6][8] - Management emphasized the importance of AI investments to enhance operational efficiency and improve margins [18][19] Q&A Session Summary Question: Can you speak to tech investments, including AI and advancements for physicians? - Management highlighted three components of AI-related investments, focusing on enhancing margins and shareholder returns through data utilization [18][19] Question: Can you provide color on Practice Collection trends for Q4 and 2026 guidance? - Management noted that Q4 collections were impacted by prior period adjustments and that 2026 guidance does not assume similar growth rates [25][26] Question: What are your thoughts on utilization trends and changes around ACA and Medicaid enrollment? - Management expects ambulatory utilization to remain elevated, while acknowledging potential churn in the Medicaid population [32][33] Question: Can you help bridge historical expectations for EBITDA to free cash flow conversion? - Management confirmed an expectation of 80% conversion for 2026, factoring in cash taxes [36][40] Question: Any updated thoughts around capital deployment priorities? - Management reiterated a focus on deploying capital to compound the business while maintaining a sufficient cash balance for flexibility [42][44] Question: Can you provide an update on the Evolent acquisition and its synergies? - Management expressed excitement about the Evolent acquisition and the potential for cross-selling opportunities [50][51] Question: How do you plan to increase the savings rate for the Evolent ACO? - Management indicated that improvements will take time and will involve implementing best practices from Privia's existing operations [54][56] Question: What is the expected impact of the LEAD Model on Privia's strategy? - Management is evaluating the LEAD Model and sees potential opportunities as ACO REACH sunsets [89]